Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q3
Sell
-35,668
Closed -$3.11M 336
2025
Q2
$3.11M Sell
35,668
-183
-0.5% -$14.3K 0.08% 111
2025
Q1
$2.45M Buy
35,851
+8,947
+33% +$730K 0.06% 111
2024
Q4
$2.09M Buy
26,904
+2,547
+10% +$189K 0.05% 151
2024
Q3
$1.63M Buy
24,357
+9,357
+62% +$768K 0.04% 203
2024
Q2
$1.7M Buy
+15,000
New +$1.9M 0.05% 222
2024
Q1
Sell
-6,172
Closed -$766K 547
2023
Q4
$766K Sell
6,172
-18,828
-75% -$1.92M 0.02% 303
2023
Q3
$2.33M Buy
+25,000
New +$2.82M 0.04% 219

Other funds holding DXCM

UBS O'Connor's DXCM Position: Q3 2025 in Review

UBS O'Connor sold out of DexCom (DXCM) in Q3 2025, closing a stake of 35,668 shares — an estimated $3.11M sold.

UBS O'Connor first reported a position in DXCM in Q3 2023 and held it in 7 quarters. The position peaked at $3.11M in Q2 2025. 911 funds tracked by Wall St. Rank hold DXCM as of Q3 2025.

  • UBS O'Connor reported no remaining DexCom position as of Q3 2025 after selling out during the quarter.
  • UBS O'Connor sold 35,668 DexCom shares in Q3 2025, an estimated $3.11M.
  • UBS O'Connor first reported a position in DexCom in Q3 2023 and held it in 7 quarters.
  • UBS O'Connor's DexCom position peaked at $3.11M in Q2 2025.
  • 911 funds tracked by Wall St. Rank held DexCom as of Q3 2025.

Based on UBS O'Connor's 13F filing for Q3 2025, filed 14 Nov 2025.